Clinical trials: Staphylococcus Aureus Endocarditis
Bacteremia, Endocarditis, Bacterial
Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
Staphylococcus aureus is a frequent cause of primary or secondary bacteremia. It is also responsible for many cases of infective endocarditis, for which the therapeutic management is specific.
- Trial name
- BACT_URIE (NCT05522764)
- Where
- France
- Volunteers
- 247 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
This will be a pilot single-arm study consisting of 15 participants evaluating the use of oritavancin in the final consolidation phase (last two weeks of treatment) of systemic infections with Staphylococcus aureus (S.
- Trial name
- NCT03761953
- Testing
- Oritavancin Injection
- Where
- United States
- Sponsor
- University of Pennsylvania
Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.
- Conditions
- Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia, S. Aureus Bloodstream Infection
- Trial name
- DAPTO-SNAP (NCT06637332)
- Testing
- Daptomycin for Injection, Vancomycin (IV)
- Where
- 20 sites in Australia, Canada and 1 more
- Volunteers
- 300 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Blood Stream Infections, Endocarditis
Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
1. Drug resistance of G+ cocci is a severe healthcare problem. According to the Ministry of Health National Antimicrobial Resistant Investigation Net (mohnarin) surveillance report, the isolation rate of MRSA is some 60% in…
- Conditions
- Blood Stream Infections, Endocarditis, MRSA
- Trial name
- NCT02443064
- Testing
- Vancomycin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang University
Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder)
ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis
This study evaluates safety and tolerability of endolysin-derived LSVT-1701 (tonabacase) as an add-on to standard of care (SOC) antibiotic therapy for the treatment of patients with complicated Staphylococcus aureus bacteremia…
- Conditions
- Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder), Right Sided Infective Endocarditis (Disorder), Endocarditis Infective
- Trial name
- ERASE (NCT05329168)
- Testing
- Tonabacase (LSVT-1701)
- Where
- United States
- Sponsor
- Lysovant
Infective Endocarditis
Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis
The study evaluates the efficacy and safety of fosfomycin and imipenem for the treatment of methicillin-resistant staphyloccocus aureus infective endocarditis in comparison to vancomycin, the standard therapy.
- Trial name
- NCT00871104
- Testing
- Fosfomycin and imipenem, Vancomycin
- Where
- 10 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Juan A. Arnaiz
Staphylococcus Aureus Bacteremia, Infective Endocarditis
Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).
The goal of this prospective interventionist cohort study is to assess the prevalence of infective endocarditis in patients with Staphylococcus aureus bacteremia at low risk of this complication.
- Trial name
- ET-AUREUS (NCT05862025)
- Testing
- Echocardiography evaluation
- Where
- Spain
- Volunteers
- 470 people
- Sponsor
- Puerta de Hierro University Hospital